Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years

被引：0
|
作者：
Meyer, Ulrike
Zehnter, Elmar
Mauss, Stefan
Boeker, Klaus
Lutz, Thomas
Racky, Stefan
Schmidt, Wolfgang
Ullrich, Rainer
Sbrijer, Innessa
Heyne, Renate
Schober, Andreas
John, Christine
Hey, Karl-Heinz
Bokemeyer, Bernd
Kallinowski, Birgit
Moeller, Bernd
Pape, Stefan
Alshuth, Ulrich
Hueppe, Dietrich
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A790 / A791
页数：2
相关论文
共 50 条
  • [21] Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Foster, Graham R.
    Fried, Michael W.
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Freivogel, Klaus
    Weiland, Ola
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 247 - 255
  • [22] Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus)
    Balan, V
    Zeuzem, S
    Sette, H
    Fried, M
    Jensen, D
    Pastore, G
    Marcellin, P
    Sedarati, F
    JOURNAL OF HEPATOLOGY, 2003, 38 : 19 - 19
  • [23] Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).
    Ferenci, P
    Shiffman, ML
    Fried, MW
    Sulkowski, MS
    Haeussinger, D
    Zarski, JP
    Goncales, F
    Jensen, DM
    Bonino, F
    Dhumeaux, D
    Blotner, S
    Hoffman, J
    Oliveto, J
    HEPATOLOGY, 2001, 34 (04) : 351A - 351A
  • [24] An evaluation of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for the first treatment of mild chronic hepatitis C (CHC)
    Hornberger, J
    Dusheiko, G
    Lewis, G
    Patel, K
    HEPATOLOGY, 2005, 42 (04) : 653A - 653A
  • [25] A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK
    Latimer, NR
    Lewis, GJ
    VALUE IN HEALTH, 2005, 8 (06) : A58 - A58
  • [26] Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    Sherman, M.
    Yoshida, E. M.
    Deschenes, M.
    Krajden, M.
    Bain, V. G.
    Peltekian, K.
    Anderson, F.
    Kaita, K.
    Simonyi, S.
    Balshaw, R.
    Lee, S. S.
    GUT, 2006, 55 (11) : 1631 - 1638
  • [27] DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV)
    Lutz, T.
    Boeker, K.
    Moog, G.
    Baumgarten, A.
    Eisenbach, C.
    Schmidt, W.
    Waizmann, M.
    Bokemeyer, B.
    Pape, S.
    Roessle, M.
    Stoehr, A.
    Lohmeyer, J.
    Witthoeft, T.
    Moeller, B.
    Loehr, H.
    Schott, E.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S182 - S182
  • [28] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [29] Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany -: A contribution to health care research
    Zehnter, E
    Mauss, S
    John, C
    Heyne, R
    Möller, B
    Bokemeyer, B
    Moog, G
    Alshuth, U
    Hüppe, D
    HEPATOLOGY, 2005, 42 (04) : 683A - 683A
  • [30] End of treatment and sustained response to peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (RBV) (COPEGUS) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC).
    Fargion, S
    Borzio, M
    Cargnel, A
    HEPATOLOGY, 2003, 38 (04) : 733A - 733A
12345